齐拉西酮与喹硫平治疗精神分裂症的临床研究

摘要

目的：分析研究齐拉西酮与喹硫平治疗精神分裂症的疗效。方法将2014年1月～8月在我院治疗的84例符合中国精神障碍分类与诊断标准第三版（CCMD-3）的精神分裂症患者，随机分成齐拉西酮治疗组（观察组）和喹硫平组治疗组（对照组），各42例，治疗8周后评定临床疗效和不良反应。结果治疗8周后，观察组有效率为88.10％，对照组有效率为83.34％，两种药物疗效差异无统计学意义（P＞0.05）；治疗后两组PANSS评分均较治疗前降低（P＜0.05），组间比较差异无统计学意义（P＞0.05）；观察组副反应发生率明显低于对照组（P＜0.05）。结论齐拉西酮为一种安全有效且耐受性较好的抗精神病药，值得在临床上使用。%Objective To observe the clinical effects of ziprasidone and quetiapine in the treatment of schizophren.Methods A retrospective analysis of clinical data was conducted in 84 patients with schizophren who were admitted in our hospital from January 2014 to August,and they were randomly divided into observation group and control group, each group contained 42 cases.The observation group were treated with ziprasidone, the control group were treated with quetiapine.The curative effects were compared between the two groups after treatment. Results The total effective rate of the observation group was 88.10% ,the control group was 83.34%,so the difference was no statistically signiifcant(P>0.05),The PANSS score in both groups had signiifcant improvement as compared with before treatment(P<0.05),but the two group was no statistically signiifcant(P>0.05), The side reaction in the observation group was signiifcantly lower than in control group (P<0.05).Conclusion The use of ziprasidone in treatment of schizophren is better and worthy of clinical application.